Why the study?
Does dipyridamole reduce plasma renin activity and aldosterone in hypertensive patients?
Does dipyridamole reduce plasma renin activity and aldosterone in hypertensive patients?
Dipyridamole decreases plasma renin activity and aldosterone in hypertensive patients, suggesting that endogenous adenosine inhibits the renin-angiotensin-aldosterone system.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for adenosine-mediated RAAS inhibition in hypertension; larger trials needed before considering clinical use.
Taddei et al. (1992) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: